Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Executives of Juno Therapeutics Under Investigation

Schubert Jonckheer & Kolbe
Posted on: 10 Aug 17

SAN FRANCISCO, Aug. 8, 2017 /PRNewswire/ -- Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO) breached their fiduciary duties to Juno and its shareholders by exposing Juno to civil liability for failing to disclose patient deaths in the Phase II/ROCKET trial of its leading product candidate, JCAR015, during the period June 24, 2016 to November 22, 2016. 

A motion to dismiss a class action lawsuit against Juno and its CEO, CFO and Chief Medical Officer was recently denied by the U.S. District Court for the Western District of Washington. The class action alleges that the defendants recklessly failed to tell investors that patients were dying from toxic side effects associated with JCAR015 during the treatment's Phase II trial.  The plaintiffs allege that the defendants falsely represented that the deaths were attributable to the use of fludarabine in combination with JCAR015 when they actually knew that fludarabine had nothing to do with the deaths, and instead were attributable to JCAR015 alone.  Juno is exposed to substantial potential liability through the class action.

The Schubert Law Firm's investigation concerns when and how much certain of Juno's officers and directors knew or should have known about role of JCAR015 in the patient deaths that occurred during the Phase II trial of JCAR015, and that the Company's representations regarding the role of fludarabine were false or misleading.

If you are a long-term holder of Juno stock and wish to obtain additional information about the Schubert Law Firm's investigation and your legal rights, please contact Miranda Kolbe via email at mkolbe@schubertlawfirm.com or by telephone at (415) 788-4220, or fill out the form on our website at http://classactionlawyers.com/juno.

About Schubert Jonckheer & Kolbe

Schubert Jonckheer & Kolbe has extensive experience in prosecuting securities claims, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising.  Prior results do not guarantee similar outcomes.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 10/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.